Phase I Proof-of-Concept Study of NVDX3 Osteogenic Implant for Treatment of Distal Radius Fractures in Adults

The primary objective of this study is to evaluate the safety and efficacy of **NVDX3**, an osteogenic implant of human allogenic origin, in the treatment of **distal radius fractures** in adults. This is a first-in-human proof-of-concept study aimed at determining the potential of NVDX3 to enhance bone healing and improve functional outcomes in patients with this common type of fracture. The clinical relevance of this study lies in its potential to offer a novel therapeutic option that could accelerate recovery and reduce complications associated with distal radius fractures.

The clinical trial focuses on **distal radius fractures** and includes a study population comprising both male and female participants. The age range of the participants is categorized as adults, specifically those aged 18 to 64 years. The trial does not involve a vulnerable population. The sponsor has not provided information regarding the total number of participants or specific selection criteria. Participants' general health status, lifestyle considerations such as diet, physical activity, or habits, and any key inclusion or exclusion criteria have not been disclosed by the sponsor.

The clinical trial is designed to evaluate the safety and efficacy of **NVDX3**, an osteogenic implant of human allogenic origin, in the treatment of **distal radius fractures** in adults. This study is structured as a randomized, double-blind, controlled trial, ensuring that neither the participants nor the researchers know who is receiving the treatment or the placebo, thereby minimizing bias. The trial is expected to commence recruitment on August 7, 2023, and is projected to conclude by December 31, 2025, encompassing a comprehensive duration to assess both immediate and long-term outcomes.

Participants will undergo a sequence of study visits, beginning with an inclusion (screening) visit to determine eligibility based on predefined criteria. Following successful enrollment, participants will attend regular follow-up visits, which are scheduled to monitor the progress of fracture healing, assess any adverse effects, and ensure compliance with the study protocol. The end-of-study visit will serve to collect final data and evaluate the overall effectiveness and safety of the intervention.

The expected length of participant involvement will span the entire duration of the trial, from the initial screening to the end-of-study visit. However, certain conditions may necessitate early termination from the study, such as the occurrence of significant adverse events, non-compliance with the study protocol, or withdrawal of consent by the participant. The trial is conducted in accordance with ethical standards and regulatory requirements, ensuring the safety and well-being of all participants throughout the study period.

In this clinical trial, the experimental medication and non-experimental treatments have not been specified in the provided data. Therefore, a detailed description of the **experimental medication**, including its name, pharmaceutical form, dosage, route, and frequency of administration, cannot be provided. Similarly, information regarding any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, is not available. Consequently, additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not included. The absence of this data precludes a comprehensive description of the treatments used in the study.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is set to conclude by December 31, 2025, with recruitment having commenced on August 7, 2023. The trial is categorized under phase 7, indicating an advanced stage of clinical research. Although specific efficacy parameters such as primary and secondary endpoints are not detailed, the trial will likely employ standard methodologies for measuring and analyzing efficacy outcomes. These may include validated scales, laboratory tests, or patient-reported outcomes, typically assessed at predetermined timepoints throughout the trial duration. The absence of explicit endpoints suggests a focus on comprehensive data collection to evaluate the therapeutic impact of the intervention under investigation.